91丝瓜视频

Dr. Armen Aprikian graduated from the University of Sherbrooke Medical School in Quebec in 1985 and completed his urology residency training at 91丝瓜视频 in 1990. He then pursued a 3-year research and clinical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Centre in New York City. In 1993 he was appointed Assistant Professor of Surgery (Urology) at 91丝瓜视频 and began his career as a clinical urologic oncologist. In 1998 he became the 91丝瓜视频 Division of Urology Training Program Director and in 2000 established the Annual Canadian Senior Resident Urologic Oncology Course which runs to this day. In 2004 he became the Head of the Division of Urology at 91丝瓜视频 and the Chief of Urology at the 91丝瓜视频 Health Centre (MUHC). In 2007 he became Full Professor of Surgery and Oncology and in 2009 he was appointed the Medical Director of the MUHC Cancer Care Mission and Chief of the Department of Oncology. Moreover, in 2010 he was appointed the 91丝瓜视频 Richard Tomlinson Professor in Prostate Cancer. In 2020 he was appointed as Clinical Lead of 91丝瓜视频鈥檚 Rossy Cancer Network, a network of 91丝瓜视频 Teaching Hospitals including 91丝瓜视频 Health Centre, the Jewish General Hospital, and St. Mary鈥檚 Hospital. Finally, in 2023 he became the interim Chair of the 91丝瓜视频 Gerald Bronfman Department of Oncology. Dr. Aprikian has been awarded the American Society of Clinical Oncology Young Investigator Award, the American Urologic Association Practicing Urologist Award, the 91丝瓜视频 William Dawson Scholar Career Award and the Quebec FRSQ Senior Clinician Scientist Award. He has obtained independent peer-reviewed grants from several organizations including the US Department of Defense and the National Cancer Institute. In addition, in 2004 he was a founding member of Procure, a Quebec-based Prostate Cancer Foundation dedicated to research and public awareness. He serves or has served on several Boards of Directors or executive committees, including the Rossy Cancer Network of 91丝瓜视频, Cedars Cancer Foundation, Goodman Cancer Research Centre, MUHC-Research Institute, Canadian Urology Association, Bladder Cancer Canada, and Procure Alliance. He serves on the Programme Quebecois de Cancerologie strategic orientations committee, and provides expert opinion to INESSS on cancer drugs. He is actively involved in a leadership role in national and provincial guidelines in prostate, bladder and testicular cancer surgery outcomes and has published over 260 peer-reviewed original scientific papers. Finally, in 2022 he was elected as President of the Canadian Urology Association.